COHEN & STEERS INC (CNS) Fundamental Analysis & Valuation
NYSE:CNS • US19247A1007
Current stock price
63.26 USD
+0.6 (+0.96%)
Last:
This CNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CNS Profitability Analysis
1.1 Basic Checks
- CNS had positive earnings in the past year.
- CNS had a negative operating cash flow in the past year.
- Each year in the past 5 years CNS has been profitable.
- CNS had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- The Return On Assets of CNS (17.48%) is better than 96.23% of its industry peers.
- The Return On Equity of CNS (27.27%) is better than 92.05% of its industry peers.
- CNS's Return On Invested Capital of 20.96% is amongst the best of the industry. CNS outperforms 97.07% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CNS is significantly above the industry average of 7.24%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.48% | ||
| ROE | 27.27% | ||
| ROIC | 20.96% |
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
1.3 Margins
- With a decent Profit Margin value of 27.66%, CNS is doing good in the industry, outperforming 71.13% of the companies in the same industry.
- In the last couple of years the Profit Margin of CNS has grown nicely.
- With a decent Operating Margin value of 31.68%, CNS is doing good in the industry, outperforming 61.09% of the companies in the same industry.
- CNS's Operating Margin has declined in the last couple of years.
- The Gross Margin of CNS (86.84%) is better than 91.63% of its industry peers.
- In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.68% | ||
| PM (TTM) | 27.66% | ||
| GM | 86.84% |
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
2. CNS Health Analysis
2.1 Basic Checks
- The number of shares outstanding for CNS has been increased compared to 1 year ago.
- The number of shares outstanding for CNS has been increased compared to 5 years ago.
- CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 7.26 indicates that CNS is not in any danger for bankruptcy at the moment.
- CNS has a Altman-Z score of 7.26. This is amongst the best in the industry. CNS outperforms 92.05% of its industry peers.
- CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.26 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 0.98 indicates that CNS may have some problems paying its short term obligations.
- CNS's Current ratio of 0.98 is in line compared to the rest of the industry. CNS outperforms 42.68% of its industry peers.
- A Quick Ratio of 0.98 indicates that CNS may have some problems paying its short term obligations.
- CNS's Quick ratio of 0.98 is in line compared to the rest of the industry. CNS outperforms 43.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.98 |
3. CNS Growth Analysis
3.1 Past
- The Earnings Per Share has been growing slightly by 5.80% over the past year.
- Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 3.74% on average per year.
- CNS shows a small growth in Revenue. In the last year, the Revenue has grown by 7.04%.
- The Revenue has been growing slightly by 5.73% on average over the past years.
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%
3.2 Future
- The Earnings Per Share is expected to grow by 8.66% on average over the next years. This is quite good.
- CNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.70% yearly.
EPS Next Y8.82%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
EPS Next 5Y8.66%
Revenue Next Year3.84%
Revenue Next 2Y4.21%
Revenue Next 3Y-0.11%
Revenue Next 5Y6.7%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. CNS Valuation Analysis
4.1 Price/Earnings Ratio
- CNS is valuated rather expensively with a Price/Earnings ratio of 20.41.
- Compared to the rest of the industry, the Price/Earnings ratio of CNS indicates a slightly more expensive valuation: CNS is more expensive than 65.27% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.17, CNS is valued a bit cheaper.
- A Price/Forward Earnings ratio of 18.75 indicates a rather expensive valuation of CNS.
- CNS's Price/Forward Earnings ratio is in line with the industry average.
- CNS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.05.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.41 | ||
| Fwd PE | 18.75 |
4.2 Price Multiples
- 75.73% of the companies in the same industry are more expensive than CNS, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 16.42 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- CNS has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.31
PEG (5Y)5.46
EPS Next 2Y10.9%
EPS Next 3Y8.22%
5. CNS Dividend Analysis
5.1 Amount
- CNS has a Yearly Dividend Yield of 4.41%, which is a nice return.
- CNS's Dividend Yield is comparable with the industry average which is at 6.90.
- Compared to an average S&P500 Dividend Yield of 1.89, CNS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.41% |
5.2 History
- The dividend of CNS decreases each year by -0.61%.
- CNS has paid a dividend for at least 10 years, which is a reliable track record.
- CNS has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-0.61%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- CNS pays out 82.84% of its income as dividend. This is not a sustainable payout ratio.
DP82.84%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
CNS Fundamentals: All Metrics, Ratios and Statistics
NYSE:CNS (4/6/2026, 12:39:13 PM)
63.26
+0.6 (+0.96%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)01-22 2026-01-22/amc
Earnings (Next)04-22 2026-04-22/amc
Inst Owners56.27%
Inst Owner Change0%
Ins Owners23%
Ins Owner Change5.68%
Market Cap3.25B
Revenue(TTM)553.87M
Net Income(TTM)153.22M
Analysts48
Price Target71.91 (13.67%)
Short Float %5.07%
Short Ratio3.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.41% |
Yearly Dividend2.5
Dividend Growth(5Y)-0.61%
DP82.84%
Div Incr Years3
Div Non Decr Years3
Ex-Date03-09 2026-03-09 (0.67)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.25%
Min EPS beat(2)-0.99%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-1.02%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)2
Avg EPS beat(8)-1.07%
EPS beat(12)4
Avg EPS beat(12)0.08%
EPS beat(16)8
Avg EPS beat(16)0.68%
Revenue beat(2)1
Avg Revenue beat(2)0.17%
Min Revenue beat(2)-0.52%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.18%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.8%
Revenue NY rev (1m)-3.21%
Revenue NY rev (3m)-5.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.41 | ||
| Fwd PE | 18.75 | ||
| P/S | 5.87 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.79 | ||
| P/tB | 6 | ||
| EV/EBITDA | 16.42 |
EPS(TTM)3.1
EY4.9%
EPS(NY)3.37
Fwd EY5.33%
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS10.78
BVpS10.94
TBVpS10.55
PEG (NY)2.31
PEG (5Y)5.46
Graham Number27.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.48% | ||
| ROE | 27.27% | ||
| ROCE | 27.12% | ||
| ROIC | 20.96% | ||
| ROICexc | 27.04% | ||
| ROICexgc | 30.2% | ||
| OM | 31.68% | ||
| PM (TTM) | 27.66% | ||
| GM | 86.84% | ||
| FCFM | N/A |
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
ROICexc(3y)33.62%
ROICexc(5y)61.08%
ROICexgc(3y)38.82%
ROICexgc(5y)75.29%
ROCE(3y)30.11%
ROCE(5y)42.55%
ROICexgc growth 3Y-33.24%
ROICexgc growth 5Y-15.16%
ROICexc growth 3Y-30.82%
ROICexc growth 5Y-13.86%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
F-Score3
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 51.04% | ||
| Cap/Sales | 1.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 7.26 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)421.2%
Cap/Depr(5y)277.41%
Cap/Sales(3y)4.98%
Cap/Sales(5y)3.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
EPS Next Y8.82%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
EPS Next 5Y8.66%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%
Revenue Next Year3.84%
Revenue Next 2Y4.21%
Revenue Next 3Y-0.11%
Revenue Next 5Y6.7%
EBIT growth 1Y1.51%
EBIT growth 3Y-4.78%
EBIT growth 5Y3.6%
EBIT Next Year-2.4%
EBIT Next 3Y14.61%
EBIT Next 5Y11.96%
FCF growth 1Y-248.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-224.57%
OCF growth 3YN/A
OCF growth 5YN/A
COHEN & STEERS INC / CNS Fundamental Analysis FAQ
What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CNS.
What is the valuation status for CNS stock?
ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.
What is the profitability of CNS stock?
COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for CNS stock?
The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 20.41 and the Price/Book (PB) ratio is 5.79.
What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?
The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 8.82% in the next year.